ICP
VRTX icon

Interchange Capital Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Interchange Capital Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$254K Sell
511
-408
-44% -$181K 0.05% 344
2026
Q1 		$443K Buy
919
+299
+48% +$139K 0.14% 156
2025
Q4 		$281K Sell
620
-164
-21% -$70.7K 0.05% 316
2025
Q3 		$307K Sell
784
-268
-25% -$112K 0.06% 259
2025
Q2 		$468K Sell
1,052
-36
-3% -$16.6K 0.11% 159
2025
Q1 		$527K Buy
1,088
+52
+5% +$24.2K 0.15% 134
2024
Q4 		$418K Sell
1,036
-464
-31% -$215K 0.15% 148
2024
Q3 		$698K Buy
1,500
+107
+8% +$51.4K 0.25% 106
2024
Q2 		$653K Buy
1,393
+581
+72% +$252K 0.24% 109
2024
Q1 		$359K Buy
+812
New +$343K 0.24% 98
2023
Q4 		– Sell
-916
Closed -$318K – 162
2023
Q3 		$318K Buy
+916
New +$320K 0.25% 97
2021
Q1 		– Sell
-331
Closed -$78K – 1081
2020
Q4 		$78K Buy
+331
New +$75.9K 0.04% 338

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Interchange Capital Partners's VRTX Position: Q2 2026 in Review

Interchange Capital Partners reduced its Vertex Pharmaceuticals (VRTX) stake by 44% in Q2 2026, selling an estimated $181K and leaving 511 shares worth $254K. The position accounts for 0.05% of the portfolio, ranked #344.

Interchange Capital Partners first reported a position in VRTX in Q4 2020 and has held it in 12 quarters since. The position peaked at $698K in Q3 2024. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Interchange Capital Partners held 511 shares of Vertex Pharmaceuticals worth $254K as of Q2 2026.
  • Interchange Capital Partners sold 408 Vertex Pharmaceuticals shares in Q2 2026, an estimated $181K.
  • Vertex Pharmaceuticals made up 0.05% of Interchange Capital Partners's portfolio in Q2 2026, its #344 holding.
  • Interchange Capital Partners first reported a position in Vertex Pharmaceuticals in Q4 2020 and has held it in 12 quarters since.
  • Interchange Capital Partners's Vertex Pharmaceuticals position peaked at $698K in Q3 2024.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Interchange Capital Partners's 13F filing for Q2 2026, filed 20 Jul 2026.